Top Back to top

Incidence and outcome of CMV and EBV reactivations after autologous HSCT for autoimmune diseases: a retrospective survey from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Autoimmune Diseases Working Party (ADWP)
Type d'étude:
Numéro de l'étude:
8410033
Type de traitement à base de cellules souches:
 
Maladies:
Auto immune disorders
Titre court:
CMV EBV reactivation
Objectif principal:
To identify the cumulative incidence, risk factors and outcome of CMV/EBV viraemia (ie, virus detection without clinical symptoms), CMV/EBV disease (ie, detection of viraemia and clinically relevant end organ disease) and CMV/EBV clinically significant infection (CMV/EBV viraemia leading to pre-emptive treatment) in patients who received autologous HSCT for an autoimmune disease (AD) at 100 days and 1 year following auto-HSCT. To assess centre practice in screening and treatment of CMV and EBV in the context of auto-HSCT for AD.
Principaux critères d'inclusion:
All patients registered in the EBMT database receiving a first autologous HSCT for AD between 2009 and 2019
Pays:
 
Investigateur principal:
Tobias Alexander
Coordinateur EBMT de l'étude:
Manuela Badoglio
E-mail du coordinateur de l'étude:
manuela.badoglio@upmc.fr